Drafting and filing applications directed to nanoparticle delivery composition systems involving bi-specific antibodies, where the nanoparticle contains both an antihistamine and a FcԑRI targeting moiety. The targeting moiety binds the nanoparticle to a target cell and blocks target cell degranulation mediated by FcԑRI receptor aggregation on the cell surface.
Nanoparticle Delivery Systems and Bi-Specific Antibodies
- Post author:Michael McGurk
- Post published:June 2, 2020
- Post category:Intellectual Property Client Projects
Tags: Life Science
Please Share This Share this content
Mike McGurk has more than 30 years of experience in virtually all aspects of patent law. Working with clients ranging from small start-ups to large Fortune 100 companies, he provides counsel in due diligence matters, global portfolio development and adversarial proceedings, including litigation, post-grant reviews, interferences and re-examinations. Mike works primarily with pharmaceutical, chemical, medical device and mechanical technology businesses. For at least the last fifteen (15) years, approximately 50-70% of Mike’s work has been focused in life sciences, including ANDA litigation support and pre-filing due diligence. Mike’s practice is informed by his background as a patent examiner in the chemical arts for the United States Patent and Trademark Office (USPTO), as a litigator for ten years, and as an expert in due diligence matters. He regularly provides strategic litigation counseling support to clients across the nation, and has handled numerous patent matters before the Patent Trial and Appeal Board of the USPTO. His extensive due diligence experience includes pre-litigation, acquisition, in-license, freedom-to-operate product and/or process clearance, design around, validity and patentability matters. Mike works with teams having the appropriate technical and legal abilities.